PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
PTC Therapeutics, Inc.NASDAQ: PTCT
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $15.87M rose 109.3% year over year, ahead of the +97.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.0% from the prior quarter. Over 3 fiscal years it compounded at -33.0% a year.
Context
- Depreciation & amortization amounted to 2.2% of revenue in FY2025, down 7.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +109.3% holds above the trailing-twelve-month pace of +97.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 38.82M USD
- Year-over-year change
- -48.7%
- 4-year CAGR
- -11.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.82M | -48.7% |
| FY2024 | 2024-12-31 | 75.66M | -68.0% |
| FY2023 | 2023-12-31 | 236.59M | +83.6% |
| FY2022 | 2022-12-31 | 128.84M | +100.9% |
| FY2021 | 2021-12-31 | 64.13M | — |
Depreciation & Amortization vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 depreciation & amortization of $55.3M is the 3rd highest of the 11 companies compared; the peer median is $15.44M.
- Its year-over-year change of +97.1% is the 2nd highest of 11, against a peer median of +6.3%.
- Depreciation & amortization amounts to 5.5% of revenue for PTCT, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1B | +66925.2% | +52.5% | — | |
| LTM Sep 2026 | $134.49M | +62.6% | -7.9% | 0.0% | |
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Mar 2026 | $45.14M | +15.9% | +2.1% | 2.1% | |
| LTM Mar 2026 | $34.01M | -4.7% | +24.3% | 5.1% | |
| LTM Sep 2026 | $21.89M | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $8.99M | +4.0% | -4.3% | 12.5% | |
| LTM Jun 2026 | $6.66M | +6.4% | +17.3% | 1.5% | |
| LTM Jun 2026 | $5.07M | -7.9% | -7.1% | 0.7% | |
| LTM Jun 2026 | $2.15M | +13.8% | +6.8% | — | |
| LTM Mar 2026 | $1.62M | -35.9% | -12.1% | — | |
| Peer median (excluding PTCT) | $15.44M | +6.3% | +1.5% | 2.1% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 538.59M | 698.8M | 937.82M | 806.78M | 1.73B |
| Cost of Revenue | 32.33M | 44.68M | 65.49M | 57.4M | 71.76M |
| Gross Profit | 506.27M | 654.12M | 872.34M | 749.38M | 1.66B |
| Gross Margin | 94.0% | 93.6% | 93.0% | 92.9% | 95.9% |
| Research & Development | 540.68M | 651.5M | 666.56M | 534.48M | 455.25M |
| Selling, General & Admin | 285.77M | 326M | 332.54M | 300.91M | 347.14M |
| Operating Expenses | 880.71M | 1.1B | 1.31B | 1.05B | 802.39M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| EBITDA | (368.18M) | (367.78M) | (330.34M) | (120.46M) | 887.66M |
| EBITDA Margin | -68.4% | -52.6% | -35.2% | -14.9% | 51.3% |
| Operating Income | (374.44M) | (447.41M) | (439.5M) | (302.57M) | 856.51M |
| Operating Margin | -69.5% | -64.0% | -46.9% | -37.5% | 49.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 86.02M | 90.87M | 129.18M | 166.99M | 152.23M |
| Other Income / Expenses | (143.9M) | (140.08M) | (256.61M) | (60.55M) | (159.89M) |
| Income Before Tax | (518.34M) | (587.49M) | (696.11M) | (363.12M) | 696.62M |
| Pre-Tax Margin | -96.2% | -84.1% | -74.2% | -45.0% | 40.3% |
| Income Tax Expense | 5.56M | (28.47M) | (69.51M) | 176K | 13.98M |
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Net Margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (Basic) | (7.43) | (7.79) | (8.37) | (4.73) | 8.58 |
| EPS (Diluted) | (7.43) | (7.79) | (8.37) | (4.73) | 7.78 |
| Weighted Avg Shares | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M |
| Weighted Avg Shares (Diluted) | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.